Evidence map›Paper›PMID 42376036›Full record

ArticleFrontiers in pediatrics2026

Real-world effectiveness and safety of dupilumab therapy in children ≤6 years with uncontrolled persistent asthma: a propensity-matched retrospective cohort study.

Ahlam Mazi, Azizah Aljohany, Michele Fouad, Hanaa Hamadallah, Esraa M Bukhari, Doaa Bayomi, Samahir Alsulaimani, Nour Gazzaz, Muhannad Sharara, Monica Dobs

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ahlam MaziDepartment of Pediatrics, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
Azizah AljohanyChild and Women Health Department, Faculty of Medicine, Taibah University, Medina, Saudi Arabia.
Michele FouadFaculty of Medicine, Alexandria University, Alexandria, Egypt.
Hanaa HamadallahDepartment of Pediatrics, Faculty of Medicine, King Abdulaziz University, Rabigh, Saudi Arabia.
Esraa M BukhariDepartment of Pediatrics, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
Doaa BayomiFaculty of Medicine, Alexandria University, Alexandria, Egypt.
Samahir AlsulaimaniDepartment of Pediatrics, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
Nour GazzazDepartment of Pediatrics, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
Muhannad ShararaDepartment of Pediatrics, Medical College of Georgia, Augusta University, Augusta, GA, United States.
Monica DobsDepartment of Pediatrics, Serra Medical Clinic, Los Angeles, CA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Asthma is common in children. Dupilumab is a biological agent that showed effectiveness in older children with uncontrolled asthma; however, its efficacy and safety are lacking among the very young children (≤6) who were excluded from clinical trials. Methods: Using TriNetX, children ≤6 years old with persistent asthma who received a concomitant prescription for dupilumab for any indication, in addition to standard asthma treatment, were compared with those on standard treatment alone. Using 1:1 propensity score matching across 35 covariates, outcomes such as acute exacerbations, status asthmaticus, need for oral corticosteroid (OCS), emergency room (ER) visits, anaphylaxis, infections, and inpatient admissions were assessed at 6 and 12 months. Results: Of 44,952 patients analyzed, 301 patients were matched per group. Asthmatic children with concomitant dupilumab prescriptions were associated with a reduction in acute exacerbations at 6 and 12 months (RR 0.53 and 0.46, respectively; Conclusions: This real-world analysis shows dupilumab therapy alongside standard treatment in children ≤6 years with persistent asthma is significantly associated with reduced acute exacerbations, OCS use, and ER visits. These findings support dupilumab's clinical benefit for this vulnerable group, aiding clinical decisions.

Indexed as

asthmabiological treatmentdupilumabmonoclonal antibodiespreschool

Identifiers

PMID42376036
PMCPMC13311024

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.